PortfoliosLab logoPortfoliosLab logo
JNJ vs. CME
Performance
Return for Risk
Drawdowns
Volatility
Dividends
Financials

Performance

JNJ vs. CME - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Johnson & Johnson (JNJ) and CME Group Inc. (CME). The values are adjusted to include any dividend payments, if applicable.

Loading charts...

Returns By Period

In the year-to-date period, JNJ achieves a 13.43% return, which is significantly higher than CME's -5.50% return. Over the past 10 years, JNJ has underperformed CME with an annualized return of 10.06%, while CME has yielded a comparatively higher 14.50% annualized return.


JNJ

1D
-0.26%
1M
5.50%
YTD
13.43%
6M
16.43%
1Y
53.49%
3Y*
16.56%
5Y*
10.04%
10Y*
10.06%

CME

1D
-2.09%
1M
-10.39%
YTD
-5.50%
6M
-4.13%
1Y
-4.58%
3Y*
15.54%
5Y*
7.50%
10Y*
14.50%
*Multi-year figures are annualized to reflect compound growth (CAGR)

JNJ vs. CME - Yearly Performance Comparison


2026 (YTD)202520242023202220212020201920182017
JNJ
Johnson & Johnson
13.43%47.48%-4.81%-8.58%5.97%11.44%10.82%16.22%-5.13%24.43%
CME
CME Group Inc.
-5.50%19.83%15.41%31.32%-22.89%29.47%-6.34%9.67%32.15%32.35%

Correlation

The correlation between JNJ and CME is 0.19, which is low. Their price movements are largely independent, making them effective diversification partners.


Correlation
Correlation (1Y)
Calculated over the trailing 1-year period

0.19

Correlation (3Y)
Calculated over the trailing 3-year period

0.24

Correlation (5Y)
Calculated over the trailing 5-year period

0.26

Correlation (10Y)
Calculated over the trailing 10-year period

0.26

Correlation (All Time)
Calculated using the full available price history since Dec 6, 2002

0.28

Fundamentals

Market Cap

JNJ:

$567.68B

CME:

$91.54B

EPS

JNJ:

$8.65

CME:

$11.75

PE Ratio

JNJ:

26.85

CME:

21.45

PEG Ratio

JNJ:

0.89

CME:

1.87

PS Ratio

JNJ:

5.86

CME:

13.46

PB Ratio

JNJ:

6.99

CME:

3.44

Total Revenue (TTM)

JNJ:

$96.36B

CME:

$6.76B

Gross Profit (TTM)

JNJ:

$66.60B

CME:

$5.84B

EBITDA (TTM)

JNJ:

$31.62B

CME:

$5.69B

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Return for Risk

JNJ vs. CME — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

JNJ
JNJ Risk / Return Rank: 9595
Overall Rank
JNJ Sharpe Ratio Rank: 9696
Sharpe Ratio Rank
JNJ Sortino Ratio Rank: 9797
Sortino Ratio Rank
JNJ Omega Ratio Rank: 9595
Omega Ratio Rank
JNJ Calmar Ratio Rank: 9292
Calmar Ratio Rank
JNJ Martin Ratio Rank: 9393
Martin Ratio Rank

CME
CME Risk / Return Rank: 3030
Overall Rank
CME Sharpe Ratio Rank: 3333
Sharpe Ratio Rank
CME Sortino Ratio Rank: 2727
Sortino Ratio Rank
CME Omega Ratio Rank: 2727
Omega Ratio Rank
CME Calmar Ratio Rank: 3535
Calmar Ratio Rank
CME Martin Ratio Rank: 2828
Martin Ratio Rank
The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

JNJ vs. CME - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Johnson & Johnson (JNJ) and CME Group Inc. (CME). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


JNJCMEDifference
Sharpe ratioReturn per unit of total volatility

+3.42

Sortino ratioReturn per unit of downside risk

+4.82

Omega ratioGain probability vs. loss probability

1.57

0.98

+0.59

Calmar ratioReturn relative to maximum drawdown

4.91

-0.21

+5.12

Martin ratioReturn relative to average drawdown

14.52

-0.72

+15.24

JNJ vs. CME - Sharpe Ratio Comparison

The current JNJ Sharpe Ratio is 3.19, which is higher than the CME Sharpe Ratio of -0.23. The chart below compares the historical Sharpe Ratios of JNJ and CME, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.


Loading charts...

Sharpe Ratios by Period


JNJCMEDifference

Sharpe Ratio (1Y)

Calculated over the trailing 1-year period

3.19

-0.23

+3.42

Sharpe Ratio (5Y)

Calculated over the trailing 5-year period

0.60

0.38

+0.22

Sharpe Ratio (10Y)

Calculated over the trailing 10-year period

0.55

0.61

-0.06

Sharpe Ratio (All Time)

Calculated using the full available price history

0.54

0.59

-0.05

Drawdowns

JNJ vs. CME - Drawdown Comparison

The maximum JNJ drawdown since its inception was -50.67%, smaller than the maximum CME drawdown of -77.50%. Use the drawdown chart below to compare losses from any high point for JNJ and CME.


Loading charts...

Drawdown Indicators


JNJCMEDifference

Max Drawdown

Largest peak-to-trough decline

-50.67%

-77.50%

+26.83%

Max Drawdown (1Y)

Largest decline over 1 year

-10.96%

-21.42%

+10.46%

Max Drawdown (3Y)

Largest decline over 3 years

-15.95%

-21.42%

+5.47%

Max Drawdown (5Y)

Largest decline over 5 years

-18.41%

-31.74%

+13.33%

Max Drawdown (10Y)

Largest decline over 10 years

-27.37%

-37.36%

+9.99%

Current Drawdown

Current decline from peak

-6.06%

-20.95%

+14.89%

Average Drawdown

Average peak-to-trough decline

-11.88%

-20.69%

+8.81%

Ulcer Index

Depth and duration of drawdowns from previous peaks

3.70%

6.35%

-2.65%

Volatility

JNJ vs. CME - Volatility Comparison

The current volatility for Johnson & Johnson (JNJ) is 5.80%, while CME Group Inc. (CME) has a volatility of 10.21%. This indicates that JNJ experiences smaller price fluctuations and is considered to be less risky than CME based on this measure. The chart below showcases a comparison of their rolling one-month volatility.


Loading charts...

Volatility by Period


JNJCMEDifference

Volatility (1M)

Calculated over the trailing 1-month period

5.80%

10.21%

-4.41%

Volatility (6M)

Calculated over the trailing 6-month period

12.41%

16.89%

-4.48%

Volatility (1Y)

Calculated over the trailing 1-year period

16.87%

20.38%

-3.51%

Volatility (5Y)

Calculated over the trailing 5-year period, annualized

16.87%

20.06%

-3.19%

Volatility (10Y)

Calculated over the trailing 10-year period, annualized

18.47%

23.89%

-5.42%

Dividends

JNJ vs. CME - Dividend Comparison

JNJ's dividend yield for the trailing twelve months is around 2.26%, less than CME's 4.44% yield.


PositionTTM20252024202320222021202020192018201720162015
CME
CME Group Inc.
4.44%1.83%4.48%4.58%5.05%3.00%3.24%2.74%2.42%4.20%4.90%5.41%
JNJ
Johnson & Johnson
2.26%2.48%3.40%3.00%2.52%2.45%2.53%2.57%2.74%2.38%2.73%2.87%

Financials

JNJ vs. CME - Financials Comparison

This section allows you to compare key financial metrics between Johnson & Johnson and CME Group Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


0.005.00B10.00B15.00B20.00B25.00B20222023202420252026
24.06B
1.88B
(JNJ) Total Revenue
(CME) Total Revenue
Values in USD except per share items

JNJ vs. CME - Profitability Comparison

The chart below illustrates the profitability comparison between Johnson & Johnson and CME Group Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

70.0%75.0%80.0%85.0%90.0%20222023202420252026
71.5%
88.1%
Portfolio components
JNJ - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a gross profit of 17.20B and revenue of 24.06B. Therefore, the gross margin over that period was 71.5%.

CME - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, CME Group Inc. reported a gross profit of 1.66B and revenue of 1.88B. Therefore, the gross margin over that period was 88.1%.

JNJ - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported an operating income of 6.40B and revenue of 24.06B, resulting in an operating margin of 26.6%.

CME - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, CME Group Inc. reported an operating income of 1.31B and revenue of 1.88B, resulting in an operating margin of 69.7%.

JNJ - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Johnson & Johnson reported a net income of 5.24B and revenue of 24.06B, resulting in a net margin of 21.8%.

CME - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, CME Group Inc. reported a net income of 1.15B and revenue of 1.88B, resulting in a net margin of 61.4%.


Frequently Asked Questions


JNJ and CME have a correlation of 0.19, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

CME has higher volatility (10.21%) compared to JNJ (5.80%). In terms of maximum drawdown, JNJ dropped -50.67% vs CME's -77.50%.

JNJ currently has the higher Sharpe Ratio (3.19 vs -0.23), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.

Portfolio Optimizer

Find the right allocation for JNJ and CME

Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.

Open Portfolio Optimizer